Related Experiment Video
Updated: Jul 18, 2026
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells
Jun Zhang1, Xianshu Wang, Chia-Ju Lin
1Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Abstract:
Fanconi anemia (FA) results from mutations in a group of genes whose products, including BRCA2 and BACH1/BRIP1, are known to function in one common pathway (the FA-BRCA pathway) to guard genome integrity, especially when challenged by DNA crosslinking agents, such as Cisplatin and mitomycin C (MMC). The extremely high incidence of cancer in FA patients reveals the essentialness of this pathway in tumor suppression. However, this pathway's involvement in nonFA cancers is not well understood. To evaluate the contribution of the FA-BRCA pathway to cancer, we investigated the integrity of the FA-BRCA pathway in ten human cancer cell lines. We found that the Calu-6 lung cancer cell line carries a defective FA-BRCA pathway. In this cell line, the examination of six FA proteins, essential for the activation of the FA-BRCA pathway, detected substantially reduced expression of FANCL, a catalytic subunit of the ubiquitin ligase/E3-complex. Reconstitution of FANCL in these cells restored the activation of the FA-BRCA pathway, but MMC sensitivity of the cells with a complemented FA-BRCA pathway was decreased as compared to the cells with an impaired FA-BRCA pathway. Collectively, the abnormal FANCL expression is the cause leading to a defective FA-BRCA pathway, which confers the sensitivity of Calu-6 cells to MMC. This suggests that the correlation of an intact FA-BRCA pathway with MMC resistance may emerge as a common mechanism underlying resistance to DNA crosslinking agents in cancer patients.
Insights
Fanconi anemia (FA) pathway defects, like reduced FANCL expression in Calu-6 cells, impact DNA repair and drug sensitivity. Restoring the FA-BRCA pathway can alter responses to DNA crosslinking agents like MMC.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- The Fanconi anemia (FA)-BRCA pathway is crucial for maintaining genome integrity, particularly against DNA crosslinking agents.
- Mutations in this pathway are linked to Fanconi anemia and its associated cancer predisposition.
- The role of the FA-BRCA pathway in non-Fanconi anemia cancers remains less understood.
Purpose of the Study:
- To investigate the integrity and function of the FA-BRCA pathway in various human cancer cell lines.
- To identify potential defects in this pathway and their contribution to cancer development or drug resistance.
Main Methods:
- Analysis of FA-BRCA pathway integrity in ten human cancer cell lines.
- Examination of FA protein expression, focusing on FANCL, in the Calu-6 lung cancer cell line.
- Functional assays involving FANCL reconstitution and mitomycin C (MMC) sensitivity testing.
Main Results:
- The Calu-6 lung cancer cell line exhibited a defective FA-BRCA pathway due to substantially reduced FANCL expression.
- Reconstitution of FANCL restored FA-BRCA pathway activation in Calu-6 cells.
- Cells with a complemented FA-BRCA pathway showed decreased sensitivity to MMC compared to those with an impaired pathway.
Conclusions:
- Abnormal FANCL expression causes FA-BRCA pathway defects, leading to MMC sensitivity in Calu-6 cells.
- An intact FA-BRCA pathway may correlate with resistance to DNA crosslinking agents in cancer patients.
- This pathway's integrity could be a significant factor in therapeutic responses to DNA-damaging chemotherapy.
